CASTRATE RESISTANT PROSTATE CANCER
Clinical trials for CASTRATE RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new CASTRATE RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for CASTRATE RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Targeted radiation zaps advanced prostate cancer in new trial
Disease control ENROLLING_BY_INVITATIONThis study is testing a new, personalized radiation treatment for men with advanced prostate cancer that has spread and is no longer responding to standard hormone-blocking drugs. The treatment uses a radioactive drug that seeks out and delivers radiation directly to prostate can…
Matched conditions: CASTRATE RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: British Columbia Cancer Agency • Aim: Disease control
Last updated Mar 27, 2026 12:39 UTC
-
Race study for prostate cancer drug withdrawn before start
Disease control TerminatedThis study aimed to see if race affects how well a standard prostate cancer drug combination works for men with specific genetic changes in their tumors. It planned to enroll Black, Hispanic, White, and Native American men with advanced prostate cancer that had stopped responding…
Matched conditions: CASTRATE RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Latin American Cooperative Oncology Group • Aim: Disease control
Last updated Mar 23, 2026 15:17 UTC
-
Prostate cancer drugs put to the test: which one protects your mind?
Symptom relief OngoingThis study aims to find out which of two common prostate cancer medications—enzalutamide or darolutamide—has less impact on memory, concentration, and other thinking skills. About 111 men with advanced prostate cancer will take one of the drugs and complete regular computer-based…
Matched conditions: CASTRATE RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: Alliance Foundation Trials, LLC. • Aim: Symptom relief
Last updated Mar 23, 2026 15:19 UTC